Nuclera Overview
- Year Founded
-
2013

- Status
-
Private
- Employees
-
127

- Latest Deal Type
-
Series C
- Latest Deal Amount
-
$75M
- Investors
-
22
Nuclera General Information
Description
Developer of an automated construct platform designed to power up drug discovery workflows. The company allows researchers to accelerate their protein projects by screening and synthesizing proteins on terms and bench, enabling healthcare professionals with integrated cell-free protein synthesis and digital microfluidics on smart cartridges that allow progress through automated, high-throughput protein access systems.
Contact Information
Website
www.nuclera.comCorporate Office
- One Vision Park, Station Road, Impington
- Impington
- Cambridge CB24 9NP
- England, United Kingdom
Corporate Office
- One Vision Park, Station Road, Impington
- Impington
- Cambridge CB24 9NP
- England, United Kingdom
Nuclera Timeline
Nuclera Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
12. Later Stage VC (Series C) | 06-Aug-2024 | $75M | Completed | Generating Revenue | ||
11. Grant | 06-Jun-2024 | Completed | Generating Revenue | |||
10. Accelerator/Incubator | 19-Mar-2024 | Completed | Generating Revenue | |||
9. Secondary Transaction - Private | Completed | Generating Revenue | ||||
8. Later Stage VC (Series B) | 06-Jul-2022 | Completed | Generating Revenue | |||
7. Later Stage VC (Series A) | 01-Oct-2019 | Completed | Generating Revenue | |||
6. Accelerator/Incubator | 22-Feb-2017 | Completed | Startup | |||
5. Grant | 01-Jul-2015 | Completed | Startup | |||
4. Grant | 01-Jul-2014 | $42.3K | $837K | Completed | Startup | |
3. Grant | 01-May-2014 | $167K | $837K | Completed | Startup |
Nuclera Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Series B | ||||||||
Series B | ||||||||
Ordinary | ||||||||
Ordinary | ||||||||
Ordinary | 39,499 | $0.000122 | $4.88 | $4.88 | 1x | $4.88 | 0.53% | |
Ordinary | 250,000 | $0.000122 | $2.45 | $2.45 | 1x | $2.45 | 3.38% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Nuclera Patents
Nuclera Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
GB-202505496-D0 | Assays for membrane proteins | Pending | 11-Apr-2025 | ||
GB-202505375-D0 | Assays for gpcr proteins | Pending | 10-Apr-2025 | ||
GB-202505044-D0 | Nucleic acid expression constructs | Pending | 03-Apr-2025 | ||
GB-202504053-D0 | Novel amino acid sequences and uses thereof | Pending | 20-Mar-2025 | ||
GB-202503544-D0 | Assays for membrane proteins | Pending | 11-Mar-2025 |
Nuclera Signals
Nuclera Investors (22)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
---|---|---|---|---|
Cambridge Innovation Capital | Venture Capital | Minority | ||
Elevage Medical Technologies | Growth/Expansion | Minority | ||
E-Link Holdings | Venture Capital | Minority | ||
Angel (individual) | Minority | |||
Patient Square Capital | PE/Buyout | Minority |
Nuclera Investments (1)
Nuclera’s most recent deal was a Corporate Asset Purchase with E Ink (Digital Microfluidics Unit) for . The deal was made on 12-May-2021.
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
E Ink (Digital Microfluidics Unit) | 12-May-2021 | Corporate Asset Purchase | Buildings and Property |
Nuclera FAQs
-
When was Nuclera founded?
Nuclera was founded in 2013.
-
Where is Nuclera headquartered?
Nuclera is headquartered in Cambridge, United Kingdom.
-
What is the size of Nuclera?
Nuclera has 127 total employees.
-
What industry is Nuclera in?
Nuclera’s primary industry is Biotechnology.
-
Is Nuclera a private or public company?
Nuclera is a Private company.
-
What is Nuclera’s current revenue?
The current revenue for Nuclera is
. -
How much funding has Nuclera raised over time?
Nuclera has raised $154M.
-
Who are Nuclera’s investors?
Cambridge Innovation Capital, Elevage Medical Technologies, E-Link Holdings, , and Patient Square Capital are 5 of 22 investors who have invested in Nuclera.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »